Aldosterone suppression with dopamine infusion in low-renin hypertension

O. B. Holland, C. Thomas, H. Brown, D. Schindewolf, Y. Hillier, C. Gomez-Sanchez

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

A dopaminergic mechanism has been proposed to suppress aldosterone secretion. To assess the possibility that a defect in the dopaminergic mechanism might enhance aldosterone secretion in hypertensive patients, we determined basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations before and during dopamine receptor stimulation with dopamine infusion and bromocriptine administration and dopamine receptor blockade with metoclopramide. The patient study groups included: (a) seven patients with low-renin hypertension and abnormal aldosterone suppression with sodium loading and presumed bilateral zona glomerulosa hyperplasia (ZGHP); (b) two patients with aldosterone-producing adenoma; (c) five patients with low-renin hypertension but normal aldosterone suppression with sodium loading; and (d) six patients with normal-renin hypertension. Dopamine infusion in patients with ZGHP caused PA to fall (P < 0.01) into the normal range, but did not block the enhanced (P < 0.05) aldosterone response to ACTH that is characteristic of these patients. Dopamine infusion in patients with low-renin hypertension but normal aldosterone suppression also suppressed PA (P < 0.01), whereas it had no effect upon PA in patients with normal-renin hypertension or aldosterone-producing adenoma and did not blunt the PA response to ACTH in either group. Bromocriptine administration had no effect upon basal or ACTH-stimulated PA. Dopamine infusion in patients with ZGHP also enhanced (P < 0.05) diuresis and natriuresis in comparison with normal-renin patients. Metoclopramide administration increased (P < 0.01) PA in all patients. Thus, a dopaminergic mechanism appears to be important in the regulation of aldosterone secretion in patients with ZGHP and in other low-renin hypertensives with normal aldosterone suppression with sodium loading. In contrast, this latter group does not exhibit an enhanced aldosterone response to ACTH. Both of these groups differ from normal-renin hypertensives, who have no PA suppression with dopamine infusion.

Original languageEnglish (US)
Pages (from-to)754-766
Number of pages13
JournalJournal of Clinical Investigation
Volume72
Issue number3
StatePublished - 1983

Fingerprint

Aldosterone
Renin
Dopamine
Hypertension
Zona Glomerulosa
Adrenocorticotropic Hormone
Hyperplasia
Metoclopramide
Bromocriptine
Sodium
Dopamine Receptors
Adenoma
Natriuresis
Diuresis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Holland, O. B., Thomas, C., Brown, H., Schindewolf, D., Hillier, Y., & Gomez-Sanchez, C. (1983). Aldosterone suppression with dopamine infusion in low-renin hypertension. Journal of Clinical Investigation, 72(3), 754-766.

Aldosterone suppression with dopamine infusion in low-renin hypertension. / Holland, O. B.; Thomas, C.; Brown, H.; Schindewolf, D.; Hillier, Y.; Gomez-Sanchez, C.

In: Journal of Clinical Investigation, Vol. 72, No. 3, 1983, p. 754-766.

Research output: Contribution to journalArticle

Holland, OB, Thomas, C, Brown, H, Schindewolf, D, Hillier, Y & Gomez-Sanchez, C 1983, 'Aldosterone suppression with dopamine infusion in low-renin hypertension', Journal of Clinical Investigation, vol. 72, no. 3, pp. 754-766.
Holland OB, Thomas C, Brown H, Schindewolf D, Hillier Y, Gomez-Sanchez C. Aldosterone suppression with dopamine infusion in low-renin hypertension. Journal of Clinical Investigation. 1983;72(3):754-766.
Holland, O. B. ; Thomas, C. ; Brown, H. ; Schindewolf, D. ; Hillier, Y. ; Gomez-Sanchez, C. / Aldosterone suppression with dopamine infusion in low-renin hypertension. In: Journal of Clinical Investigation. 1983 ; Vol. 72, No. 3. pp. 754-766.
@article{f0d8f4d00b6147918c12d23fdf5a4c15,
title = "Aldosterone suppression with dopamine infusion in low-renin hypertension",
abstract = "A dopaminergic mechanism has been proposed to suppress aldosterone secretion. To assess the possibility that a defect in the dopaminergic mechanism might enhance aldosterone secretion in hypertensive patients, we determined basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations before and during dopamine receptor stimulation with dopamine infusion and bromocriptine administration and dopamine receptor blockade with metoclopramide. The patient study groups included: (a) seven patients with low-renin hypertension and abnormal aldosterone suppression with sodium loading and presumed bilateral zona glomerulosa hyperplasia (ZGHP); (b) two patients with aldosterone-producing adenoma; (c) five patients with low-renin hypertension but normal aldosterone suppression with sodium loading; and (d) six patients with normal-renin hypertension. Dopamine infusion in patients with ZGHP caused PA to fall (P < 0.01) into the normal range, but did not block the enhanced (P < 0.05) aldosterone response to ACTH that is characteristic of these patients. Dopamine infusion in patients with low-renin hypertension but normal aldosterone suppression also suppressed PA (P < 0.01), whereas it had no effect upon PA in patients with normal-renin hypertension or aldosterone-producing adenoma and did not blunt the PA response to ACTH in either group. Bromocriptine administration had no effect upon basal or ACTH-stimulated PA. Dopamine infusion in patients with ZGHP also enhanced (P < 0.05) diuresis and natriuresis in comparison with normal-renin patients. Metoclopramide administration increased (P < 0.01) PA in all patients. Thus, a dopaminergic mechanism appears to be important in the regulation of aldosterone secretion in patients with ZGHP and in other low-renin hypertensives with normal aldosterone suppression with sodium loading. In contrast, this latter group does not exhibit an enhanced aldosterone response to ACTH. Both of these groups differ from normal-renin hypertensives, who have no PA suppression with dopamine infusion.",
author = "Holland, {O. B.} and C. Thomas and H. Brown and D. Schindewolf and Y. Hillier and C. Gomez-Sanchez",
year = "1983",
language = "English (US)",
volume = "72",
pages = "754--766",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "3",

}

TY - JOUR

T1 - Aldosterone suppression with dopamine infusion in low-renin hypertension

AU - Holland, O. B.

AU - Thomas, C.

AU - Brown, H.

AU - Schindewolf, D.

AU - Hillier, Y.

AU - Gomez-Sanchez, C.

PY - 1983

Y1 - 1983

N2 - A dopaminergic mechanism has been proposed to suppress aldosterone secretion. To assess the possibility that a defect in the dopaminergic mechanism might enhance aldosterone secretion in hypertensive patients, we determined basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations before and during dopamine receptor stimulation with dopamine infusion and bromocriptine administration and dopamine receptor blockade with metoclopramide. The patient study groups included: (a) seven patients with low-renin hypertension and abnormal aldosterone suppression with sodium loading and presumed bilateral zona glomerulosa hyperplasia (ZGHP); (b) two patients with aldosterone-producing adenoma; (c) five patients with low-renin hypertension but normal aldosterone suppression with sodium loading; and (d) six patients with normal-renin hypertension. Dopamine infusion in patients with ZGHP caused PA to fall (P < 0.01) into the normal range, but did not block the enhanced (P < 0.05) aldosterone response to ACTH that is characteristic of these patients. Dopamine infusion in patients with low-renin hypertension but normal aldosterone suppression also suppressed PA (P < 0.01), whereas it had no effect upon PA in patients with normal-renin hypertension or aldosterone-producing adenoma and did not blunt the PA response to ACTH in either group. Bromocriptine administration had no effect upon basal or ACTH-stimulated PA. Dopamine infusion in patients with ZGHP also enhanced (P < 0.05) diuresis and natriuresis in comparison with normal-renin patients. Metoclopramide administration increased (P < 0.01) PA in all patients. Thus, a dopaminergic mechanism appears to be important in the regulation of aldosterone secretion in patients with ZGHP and in other low-renin hypertensives with normal aldosterone suppression with sodium loading. In contrast, this latter group does not exhibit an enhanced aldosterone response to ACTH. Both of these groups differ from normal-renin hypertensives, who have no PA suppression with dopamine infusion.

AB - A dopaminergic mechanism has been proposed to suppress aldosterone secretion. To assess the possibility that a defect in the dopaminergic mechanism might enhance aldosterone secretion in hypertensive patients, we determined basal and adrenocorticotropic hormone (ACTH)-stimulated plasma aldosterone (PA), cortisol, renin activity, and potassium concentrations before and during dopamine receptor stimulation with dopamine infusion and bromocriptine administration and dopamine receptor blockade with metoclopramide. The patient study groups included: (a) seven patients with low-renin hypertension and abnormal aldosterone suppression with sodium loading and presumed bilateral zona glomerulosa hyperplasia (ZGHP); (b) two patients with aldosterone-producing adenoma; (c) five patients with low-renin hypertension but normal aldosterone suppression with sodium loading; and (d) six patients with normal-renin hypertension. Dopamine infusion in patients with ZGHP caused PA to fall (P < 0.01) into the normal range, but did not block the enhanced (P < 0.05) aldosterone response to ACTH that is characteristic of these patients. Dopamine infusion in patients with low-renin hypertension but normal aldosterone suppression also suppressed PA (P < 0.01), whereas it had no effect upon PA in patients with normal-renin hypertension or aldosterone-producing adenoma and did not blunt the PA response to ACTH in either group. Bromocriptine administration had no effect upon basal or ACTH-stimulated PA. Dopamine infusion in patients with ZGHP also enhanced (P < 0.05) diuresis and natriuresis in comparison with normal-renin patients. Metoclopramide administration increased (P < 0.01) PA in all patients. Thus, a dopaminergic mechanism appears to be important in the regulation of aldosterone secretion in patients with ZGHP and in other low-renin hypertensives with normal aldosterone suppression with sodium loading. In contrast, this latter group does not exhibit an enhanced aldosterone response to ACTH. Both of these groups differ from normal-renin hypertensives, who have no PA suppression with dopamine infusion.

UR - http://www.scopus.com/inward/record.url?scp=0021078545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021078545&partnerID=8YFLogxK

M3 - Article

VL - 72

SP - 754

EP - 766

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 3

ER -